Cannabis and psychosis: Is there evidence of causal association?

It has been well known since historic times that cannabis may cause a variety of psychiatric symptoms. In fact, the desire to take cannabis or marijuana is primarily to obtain mental effects, and the line may be thin even in an occasional user between experiencing a pleasant and exciting psychoactive effect and a real psychotic episode. “Cannabis psychosis” is a term widely used for psychotic episodes resulting from cannabis use. These occur during or shortly after intake and may last days or weeks, but subside after discontinuation of the drug. They may require hospitalization and medication. Comprehensive summaries of mental health effects of cannabis have been published by Murray and Hall & Degenhardt.

It has often been debated whether use of cannabis can cause long-term psychotic states, and in particular schizophrenia and other chronic psychoses. Seeing patients with a combination of heavy cannabis use and schizophrenia, I was intrigued to assess the causal direction of the association. It was in the 1980s when I found out there was a survey on drug use in a national cohort of 50,000 Swedish 18-19 year old male conscripts (one year of military service was compulsory in Sweden until 2010) that we could link to data on occurrence of schizophrenia later in life. We found that those who reported use of cannabis in adolescence had a doubled risk of schizophrenia compared to those who did not use cannabis. With data on social background, psychological characteristics, and psychiatric condition assessed at conscription, we could control for such factors that might influence the association.

We have continued to follow this cohort and the men are now over 50 years old. The contribution of cannabis to new cases of schizophrenia has declined in occasional users but those who reported heavy use of cannabis in adolescence still have a twofold increased risk of schizophrenia, even at older ages. We do not know whether this is due to continued use of cannabis, or whether heavy early use could indeed have had very long lasting effects.

In recent years, several other studies have also found an association between cannabis use and later onset of chronic psychosis. A review was published in 2007 concluding that there is now “sufficient evidence to warn young people that using cannabis could increase the risk of developing a psychotic illness later in life.” The paper was accompanied by an editorial in which the prestigious journal the Lancet admitted that they had previously underestimated the risk of harmful effects of cannabis.

We recently studied the pattern of care of the patients with schizophrenia in our cohort of male conscripts, and it turns out that those patients with a history of cannabis use had double the number of total days in hospital and around double the number of hospitalizations that were twice as long in duration of those who did not have a history of cannabis use.

Thus, there is now evidence that cannabis is indeed a contributory cause of chronic psychoses, including schizophrenia. Certainly, cannabis is not the only cause of chronic psychosis. There generally needs to be other factors, such as genetic factors, personality characteristics, etc. to cause schizophrenia or other long-standing psychoses. It has been shown that the risk of psychosis in cannabis users is especially strong in psychologically vulnerable persons. Thus young people, and especially persons with mental health illness, should be warned about the risk of chronic psychotic disorders as an effect of cannabis use. Not only because of the risk of chronic psychosis, but also a number of other negative physical and mental side effects.

*Please note that the material presented here does not necessarily imply endorsement or agreement by individuals at the Centre for Addictions Research of BC

Image

Peter Allebeck, Professor of Social Medicine, Karolinska Institute, Stockholm, Sweden

 

 

Cannabis: the Exit Drug

Cannabis is neither completely harmless, nor is it a cure-all, but with polls showing that Canadians overwhelmingly support cannabis policy reform, it’s fair to assume that most people no longer believe that legalization would lead to the end of the world.  Yet, some who support reform nonetheless have concerns that adding yet another legal drug (alongside alcohol, tobacco and pharmaceuticals) for society to struggle with might result in an increase in use.

But what if the legalization of adult access to cannabis also resulted in a reduction in the use of alcohol and other drugs?  What if rather than being a gateway drug, cannabis actually proved to be an exit drug from problematic substance use? A growing body of research on a theory called cannabis substitution effect suggests just that.

In a nutshell, substitution effect is an economic theory that suggests that variations in the availability of one product may affect the use of another.  Perhaps the best example of deliberate drug substitution is the common prescription use of methadone as a substitute for heroin, or e-cigarettes or nicotine patches rather than tobacco smoking.

However, substitution effect can be also be the unintended result of public policy shifts or other social changes, such as changes in the cost, legal status or availability of a substance.  For example, in 13 U.S. states that decriminalized the personal recreational use of cannabis in the 1970s, research found that users shifted from using harder drugs to marijuana after its legal risks were decreased (Model, 1993).

Findings from Australia’s 2001 National Drug Strategy Household Survey specifically identify cannabis substitution effect, indicating 56.6% of people who used heroin substituted cannabis when their substance of choice was unavailable.  The survey also found that 31.8% of people who use pharmaceutical analgesics for nonmedical purposes reported using cannabis when painkillers weren’t available (Aharonovich et al., 2002).

Additionally, a 2011 survey of 404 medical cannabis patients in Canada that colleagues and I conducted found that over 75% of respondents reported they substitute cannabis for another substance, with over 67% using cannabis as a substitute for prescription drugs, 41% as a substitute for alcohol, and 36% as a substitute for illicit substances (Lucas et al., 2012).

This and other evidence that cannabis can be a substitute for pharmaceutical opiates, alcohol and other drugs – and thereby reduce alcohol-related automobile accidents, violence and property crime, as well as disease transmission associated with injection drug use – could inform an evidence-based, public health-centered drug policy. Given the potential to decrease personal suffering and the social costs associated with addiction, further research on cannabis substitution effect appears to be justified on both economic and ethical grounds.

Maximizing the public health benefits of cannabis substitution effect could require the legalization of adult cannabis use, as currently being implemented in Colorado and Washington State. So the question is: do we have the courage to abandon long-standing drug policies based on fear, prejudice and misinformation, and instead develop strategies informed by science, reason and compassion?

 

*Please note that the material presented here does not necessarily imply endorsement or agreement by individuals at the Centre for Addictions Research of BC

Image

Philippe Lucas is a Graduate Researcher with the Centre for Addictions Research of BC, President of the Multidisciplinary Association of Psychedelic Studies Canada, and a founding Board member of the Canadian Drug Policy Coalition. In 2012 he was awarded the Queen Elizabeth II Diamond Jubilee Medal for his work on medical cannabis.